dgn-np:NP261910.RAb2qh20YdHDTPUQ8NvAJ5X4FWfkqAQn_C08vyJ3kvkWU130_provenance {
  dgn-np:NP261910.RAb2qh20YdHDTPUQ8NvAJ5X4FWfkqAQn_C08vyJ3kvkWU130_assertion dcterms:description "[Nevertheless, overexpression of Bcl-2 may result in 'oncogene addiction' of the cancer cell, which can be exploited by using BH3-domain inhibitors alone or in combination with other agents, including conventional chemotherapeutics (such as doxorubicin) or novel targeted therapies (such as the proteasome inhibitor bortezomib), for the treatment of aggressive thyroid cancer, including the medullary and anaplastic types.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ;
    wi:evidence dgn-void:source_evidence_literature ;
    sio:SIO_000772 miriam-pubmed:17848408 ;
    prov:wasDerivedFrom dgn-void:befree-20150227 ;
    prov:wasGeneratedBy eco:ECO_0000203 .
  dgn-void:befree-20150227 pav:importedOn "2015-02-27"^^xsd:date .
  dgn-void:source_evidence_literature a eco:ECO_0000212 ;
    rdfs:comment "Gene-disease associations inferred from text-mining the literature."@en ;
    rdfs:label "DisGeNET evidence - LITERATURE"@en .
}